UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File No. 001-38080
Biohaven Pharmaceutical Holding Company Ltd.
(Exact name of registrant as specified in its charter)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(203) 404-0410
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Shares, no par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | ☒ | |
Rule 12g-4(a)(2) | ☐ | |
Rule 12h-3(b)(1)(i) | ☒ | |
Rule 12h-3(b)(1)(ii) | ☐ | |
Rule 15d-6 | ☐ | |
Rule 15d-22(b) | ☐ |
Approximate number of holders of record as of the certification or notice date: One.
Pursuant to the requirements of the Securities Exchange Act of 1934, Biohaven Pharmaceutical Holding Company Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| Biohaven Pharmaceutical Holding Company Ltd. | ||||||
| Date: | October 14, 2022 | By: | /s/ Paloma Fernández-Montes Moraleda | |||
| Paloma Fernández-Montes Moraleda | ||||||
| President | ||||||
